https://healthobserverbermuda.com/article/906800541-revolution-medicines-to-present-updated-phase-1-clinical-data-for-zoldonrasib-in-patients-with-previously-treated-kras-g12d-non-small-cell-lung-cancer Health Observer Bermuda en PressRelease 2026-04-19T18:00:00+00:00 Revolution Medicines to Present Updated Phase 1 Clinical Data for Zoldonrasib in Patients with Previously Treated KRAS G12D Non-Small Cell Lung Cancer at the 2026 AACR Annual Meeting https://ml.globenewswire.com/media/771b34d9-586d-435a-a976-ab0ab847571b/small/balanced-green-primary-logo-medium-1000px-png.png https://healthobserverbermuda.com/article/906786185-molecular-partners-presents-three-posters-at-aacr-2026-with-new-preclinical-data-for-first-switch-darpin-t-cell-engager-mp0632-and-dll3-radio-darpin Health Observer Bermuda en PressRelease 2026-04-19T16:00:00+00:00 Molecular Partners presents three posters at AACR 2026, with new preclinical data for first Switch-DARPin T cell engager MP0632 and DLL3 Radio-DARPin MP0712 https://ml.globenewswire.com/media/ac0d728a-e43a-4d2b-a9c5-52e74d0dd1eb/small/molecularpartners-logo-jpg.jpg https://healthobserverbermuda.com/article/906641487-herz-p1-smart-oximeter-claims-evaluated-best-pulse-oxygen-monitor-device-on-the-market-with-clinical-grade-accuracy Health Observer Bermuda en PressRelease 2026-04-18T23:25:01+00:00 Herz P1 Smart Oximeter Claims Evaluated: Best Pulse Oxygen Monitor Device on the Market with Clinical-Grade Accuracy https://zingfast.com/wp-content/uploads/2026/04/Herz-P1-Smart-Oximeter.jpg https://healthobserverbermuda.com/article/906622464-vigor-boost-gummies-claims-evaluated-the-forcevital-male-enhancement-formula-under-investigation Health Observer Bermuda en PressRelease 2026-04-18T21:34:15+00:00 Vigor Boost Gummies Claims Evaluated: The ForceVital Male Enhancement Formula Under Investigation https://zingfast.com/wp-content/uploads/2026/04/Vigor-Boost-Gummies.jpg https://healthobserverbermuda.com/article/906601019-slimleaf-claims-evaluated-the-fitburn-formula-using-slim-leaf-ingredients-for-weight-loss Health Observer Bermuda en PressRelease 2026-04-18T20:10:35+00:00 SlimLeaf Claims Evaluated: The FitBurn Formula Using Slim Leaf Ingredients for Weight Loss https://zingfast.com/wp-content/uploads/2026/04/SlimLeaf.jpg https://healthobserverbermuda.com/article/906577634-pliant-therapeutics-announces-presentation-of-updated-data-from-the-phase-1-trial-of-pln-101095-in-patients-with-ici-refractory-solid-tumors-at-the Health Observer Bermuda en PressRelease 2026-04-18T17:31:00+00:00 Pliant Therapeutics Announces Presentation of Updated Data from the Phase 1 Trial of PLN-101095 in Patients with ICI-Refractory Solid Tumors at the 2026 AACR Annual Meeting https://ml.globenewswire.com/media/e31d4c37-738e-4662-861d-675c8c564317/medium/figure-1.jpg https://healthobserverbermuda.com/article/906577555-theriva-biologics-anuncia-la-pr-xima-presentaci-n-de-datos-adicionales-del-ensayo-cl-nico-virage-de-fase-2b-del-vcn-01-para-el-c-ncer-de-p-ncreas Health Observer Bermuda en PressRelease 2026-04-18T17:17:08+00:00 Theriva™ Biologics anuncia la próxima presentación de datos adicionales del ensayo clínico VIRAGE de Fase 2b del VCN-01 para el cáncer de páncreas metastásico en la Reunión Anual de la AACR de 2026 https://ml.globenewswire.com/media/ed41908b-8799-4f56-bc3c-acff4f4872eb/small/tovx-logo-jpg.jpg https://healthobserverbermuda.com/article/906552980-maps-welcomes-federal-action-to-advance-science-driven-psychedelic-research-and-policy Health Observer Bermuda en PressRelease 2026-04-18T15:34:50+00:00 MAPS Welcomes Federal Action to Advance Science-Driven Psychedelic Research and Policy https://ml.globenewswire.com/media/4f774750-4742-4818-be22-116e2b2085b1/small/maps-logo-2021-primary-horizontal-white-background-1200x486.jpg https://healthobserverbermuda.com/article/906501406-press-release-escmid-sanofi-s-nuvaxovid-covid-19-vaccine-showed-better-tolerability-than-mnexspike-in-head-to-head-study Health Observer Bermuda en PressRelease 2026-04-18T10:00:00+00:00 Press Release: ESCMID: Sanofi's Nuvaxovid COVID-19 vaccine showed better tolerability than mNEXSPIKE in head-to-head study https://ml-eu.globenewswire.com/media/06da731a-67a1-4258-939f-6ef0531ee3bf/small/sanofi-new-logo-jpg.jpg https://healthobserverbermuda.com/article/906501531-communiqu-de-presse-escmid-le-nuvaxovid-vaccin-contre-la-covid-19-de-sanofi-a-montr-une-meilleure-tol-rance-que-le-mnexspike-dans-une-tude Health Observer Bermuda en PressRelease 2026-04-18T10:00:00+00:00 Communiqué de presse : ESCMID : Le Nuvaxovid, vaccin contre la COVID-19 de Sanofi, a montré une meilleure tolérance que le mNEXSPIKE dans une étude comparative directe   https://ml-eu.globenewswire.com/media/06da731a-67a1-4258-939f-6ef0531ee3bf/small/sanofi-new-logo-jpg.jpg https://healthobserverbermuda.com/article/906476191-vigosurge-claims-evaluated-analyzing-the-ingredients-benefits-side-effects-risk-and-customer-complaints Health Observer Bermuda en PressRelease 2026-04-18T08:34:39+00:00 VigoSurge Claims Evaluated: Analyzing the Ingredients' Benefits, Side Effects Risk and Customer Complaints https://zingfast.com/wp-content/uploads/2026/04/VigoSurge.jpg https://healthobserverbermuda.com/article/906451168-argenx-brings-neuromuscular-leadership-to-aan-2026-with-new-data-supporting-broader-vyvgart-use-across-mg-and-cidp Health Observer Bermuda en PressRelease 2026-04-18T05:00:00+00:00 argenx Brings Neuromuscular Leadership to AAN 2026 with New Data Supporting Broader VYVGART Use Across MG and CIDP https://ml-eu.globenewswire.com/media/be37b058-e737-46dc-b05a-c2240f4da489/small/argenx-logo-default-png.png https://healthobserverbermuda.com/article/906425526-steel-flow-pro-claims-evaluated-analyzing-the-prostate-support-ingredients-side-effects-risk-and-hidden-complaints Health Observer Bermuda en PressRelease 2026-04-18T02:49:20+00:00 Steel Flow Pro Claims Evaluated: Analyzing the Prostate Support Ingredients, Side Effects Risk and Hidden Complaints https://zingfast.com/wp-content/uploads/2026/04/Steel-Flow-Pro.jpg https://healthobserverbermuda.com/article/906425477-vidacalm-claims-evaluated-analyzing-the-formula-s-ingredients-side-effects-risk-and-user-complaints Health Observer Bermuda en PressRelease 2026-04-18T01:30:16+00:00 VidaCalm Claims Evaluated: Analyzing the Formula's Ingredients, Side Effects Risk and User Complaints https://zingfast.com/wp-content/uploads/2026/04/VidaCalm.jpg https://healthobserverbermuda.com/article/906376671-iovance-biotherapeutics-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4 Health Observer Bermuda en PressRelease 2026-04-17T21:15:00+00:00 Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4) https://ml.globenewswire.com/media/d0986bd6-4603-4e31-8ed1-f23b3e123605/small/iovance-jpg.jpg https://healthobserverbermuda.com/article/906378346-keeps-hair-growth-product-claims-evaluated-topical-oral-rx-hair-loss-prescription-treatment-with-finasteride-dutasteride-minoxidil Health Observer Bermuda en PressRelease 2026-04-17T21:01:05+00:00 Keeps Hair Growth Product Claims Evaluated: Topical & Oral RX Hair Loss Prescription Treatment with Finasteride, Dutasteride & Minoxidil https://zingfast.com/wp-content/uploads/2026/04/Keeps-Hair-Growth.jpg https://healthobserverbermuda.com/article/906378336-boundless-bio-presents-preclinical-breast-cancer-data-from-its-oral-kinesin-degrader-program-at-2026-aacr-annual-meeting Health Observer Bermuda en PressRelease 2026-04-17T20:49:47+00:00 Boundless Bio Presents Preclinical Breast Cancer Data from its Oral Kinesin Degrader Program at 2026 AACR Annual Meeting https://ml.globenewswire.com/media/3b8ff619-e7af-4c58-a7f2-de0c4019068d/small/boundlessbiologo-jpg.jpg https://healthobserverbermuda.com/article/906376058-celularity-announces-receipt-of-nasdaq-notice-regarding-late-form-10-k-filing Health Observer Bermuda en PressRelease 2026-04-17T20:35:00+00:00 Celularity Announces Receipt of Nasdaq Notice Regarding Late Form 10-K Filing https://ml.globenewswire.com/media/ODBmYzBlZTctZGRjMC00YzIzLWEyYTEtODVjOGVkNjJlM2M4LTEyMTY1NjItMjAyNi0wNC0xNy1lbg==/tiny/Celularity-Inc-.png https://healthobserverbermuda.com/article/906376026-zenas-biopharma-announces-inducement-grants-under-nasdaq-listing-rule-5635-c-4 Health Observer Bermuda en PressRelease 2026-04-17T20:15:00+00:00 Zenas BioPharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) https://ml.globenewswire.com/media/11a7c081-eaf9-4e1d-b413-227c20d8d41a/small/zenas-logo-jpg.jpg https://healthobserverbermuda.com/article/906375383-alx-oncology-reports-inducement-grant-as-permitted-by-the-nasdaq-listing-rules Health Observer Bermuda en PressRelease 2026-04-17T20:05:00+00:00 ALX Oncology Reports Inducement Grant as permitted by the Nasdaq Listing Rules https://ml.globenewswire.com/media/0a1b4459-3df3-4c9f-ba29-ace8d7ad1b9a/small/alx-01-stacked-white-png.png https://healthobserverbermuda.com/article/906375426-theriva-biologics-announces-upcoming-presentation-of-additional-data-from-the-virage-phase-2b-clinical-trial-of-vcn-01-in-metastatic-pancreatic Health Observer Bermuda en PressRelease 2026-04-17T20:05:00+00:00 Theriva™ Biologics Announces Upcoming Presentation of Additional Data from the VIRAGE Phase 2b Clinical Trial of VCN-01 in Metastatic Pancreatic Cancer at AACR 2026 Annual Meeting https://ml.globenewswire.com/media/ed41908b-8799-4f56-bc3c-acff4f4872eb/small/tovx-logo-jpg.jpg https://healthobserverbermuda.com/article/906375629-4dmt-announces-new-employment-inducement-grants Health Observer Bermuda en PressRelease 2026-04-17T20:05:00+00:00 4DMT Announces New Employment Inducement Grants https://ml.globenewswire.com/media/027d40cf-145a-47b2-a0b8-823759376823/small/logo-2x-png.png https://healthobserverbermuda.com/article/906375662-camp4-therapeutics-announces-inducement-grants-under-nasdaq-listing-rule-5635-c-4 Health Observer Bermuda en PressRelease 2026-04-17T20:05:00+00:00 CAMP4 Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) https://ml.globenewswire.com/media/72048fc6-0a8d-4ed2-9be8-ec0ee0afd8ba/small/cmp4-21-logo-full-color-jpg.jpg https://healthobserverbermuda.com/article/906376371-oric-pharmaceuticals-presents-preclinical-data-to-support-the-potential-of-rinzimetostat-across-prostate-cancer-and-in-emerging-resistance-settings Health Observer Bermuda en PressRelease 2026-04-17T20:05:00+00:00 ORIC® Pharmaceuticals Presents Preclinical Data to Support the Potential of Rinzimetostat Across Prostate Cancer and in Emerging Resistance Settings at the 2026 American Association for Cancer Research (AACR) Annual Meeting https://ml.globenewswire.com/media/acbc0ad2-7a44-4ee7-b729-ab92d57ffafb/small/oric-png.png https://healthobserverbermuda.com/article/906376697-pyxis-oncology-to-present-new-preclinical-data-showing-synergistic-anti-tumor-activity-in-a-hnscc-model-with-mamicvo-in-combination-with-anti-pd-1-at Health Observer Bermuda en PressRelease 2026-04-17T20:05:00+00:00 Pyxis Oncology to Present New Preclinical Data Showing Synergistic Anti-Tumor Activity in a HNSCC model with maMICVO in Combination with Anti-PD-1 at AACR 2026 https://ml.globenewswire.com/media/d3b77f06-3f52-42af-8f38-e3fda9c8025b/small/pyxis-logo-jpg.jpg https://healthobserverbermuda.com/article/906377182-revolution-medicines-announces-closing-of-concurrent-upsized-public-offerings-with-aggregate-gross-proceeds-of-approximately-2-2-billion-including Health Observer Bermuda en PressRelease 2026-04-17T20:02:00+00:00 Revolution Medicines Announces Closing of Concurrent Upsized Public Offerings with Aggregate Gross Proceeds of Approximately $2.2 Billion, Including Full Exercise of Underwriters’ Option to Purchase Additional Shares https://ml.globenewswire.com/media/771b34d9-586d-435a-a976-ab0ab847571b/small/balanced-green-primary-logo-medium-1000px-png.png https://healthobserverbermuda.com/article/906375334-adagene-presents-two-posters-at-aacr-2026-with-new-data-highlighting-muzastotug-s-potential-as-a-backbone-combination-therapy-for-multiple-tumor-types Health Observer Bermuda en PressRelease 2026-04-17T20:01:00+00:00 Adagene Presents Two Posters at AACR 2026 with New Data Highlighting Muzastotug’s Potential as a Backbone Combination Therapy for Multiple Tumor Types https://ml.globenewswire.com/media/c377318b-edf7-42c0-8e7c-63a02bbe47b0/small/adagene-logo-gnw-png.png https://healthobserverbermuda.com/article/906375816-xilio-therapeutics-announces-new-preclinical-data-at-aacr-annual-meeting-for-xtx601-a-masked-t-cell-engager-targeting-cldn18-2 Health Observer Bermuda en PressRelease 2026-04-17T20:01:00+00:00 Xilio Therapeutics Announces New Preclinical Data at AACR Annual Meeting for XTX601, a Masked T Cell Engager Targeting CLDN18.2 https://ml.globenewswire.com/media/7e55cc25-f46f-423c-bf2a-e77ebaf69665/small/xilio-full-clr-logo-cmyk-png.png https://healthobserverbermuda.com/article/906376062-cardiff-oncology-presents-preclinical-data-on-its-plk1-inhibitor-onvansertib-in-combination-with-a-her2-targeted-adc-at-the-2026-aacr-annual-meeting Health Observer Bermuda en PressRelease 2026-04-17T20:01:00+00:00 Cardiff Oncology Presents Preclinical Data on its PLK1 Inhibitor Onvansertib in Combination with a HER2-Targeted ADC at the 2026 AACR Annual Meeting https://ml.globenewswire.com/media/916adb81-8173-4fbe-8095-c284c4f44cd3/small/cardiff-jpg.jpg https://healthobserverbermuda.com/article/906376104-olema-oncology-announces-preclinical-data-for-palazestrant-and-op-3136-at-the-2026-aacr-annual-meeting Health Observer Bermuda en PressRelease 2026-04-17T20:01:00+00:00 Olema Oncology Announces Preclinical Data for Palazestrant and OP-3136 at the 2026 AACR Annual Meeting https://ml.globenewswire.com/media/9c736753-c905-4bd1-ac3a-1444bea84331/small/olema-logo-rgb-png.png https://healthobserverbermuda.com/article/906376473-nexgel-moves-forward-shareholder-update-call-to-discuss-celularity-transaction-on-april-21st-at-4-30-p-m-et Health Observer Bermuda en PressRelease 2026-04-17T19:37:00+00:00 NEXGEL Moves Forward Shareholder Update Call to Discuss Celularity Transaction on April 21st at 4:30 P.M. ET https://ml.globenewswire.com/media/0e76fff8-7aee-4b60-ba26-62dda9975939/small/logo-png.png